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ABSTRACT The diagnosis of central nervous system (CNS) histoplasmosis is often
difﬁcult. Although cerebrospinal ﬂuid (CSF) (1,3)--D-glucan (BDG) is available as a bi-
ological marker for the diagnosis of fungal meningitis, there are limited data on its
use for the diagnosis of Histoplasma meningitis. We evaluated CSF BDG detection,
using the Fungitell assay, in patients with CNS histoplasmosis and controls. A total
of 47 cases and 153 controls were identiﬁed. The control group included 13 patients
with a CNS fungal infection other than histoplasmosis. Forty-nine percent of patients
with CNS histoplasmosis and 43.8% of controls were immunocompromised. The me-
dian CSF BDG level was 85 pg/ml for cases, compared to 31 pg/ml for all controls
(P  0.05) and 82 pg/ml for controls with other causes of fungal meningitis (P 
0.27). The sensitivity for detection of BDG in CSF was 53.2%, whereas the speciﬁcity
was 86.9% versus all controls and 46% versus other CNS fungal infections. CSF BDG
levels of 80 pg/ml are neither sensitive nor speciﬁc to support a diagnosis of His-
toplasma meningitis.
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The diagnosis of central nervous system (CNS) histoplasmosis is challenging. In onelarge case series study (1), cerebrospinal ﬂuid (CSF) cultures were positive for only
19.1% of patients, and culture results were often signiﬁcantly delayed after clinical
presentation. More rapid diagnosis could be achieved through detection of antibody
(sensitivity, 82.2%) and antigen (sensitivity, 78.0%) in the CSF, with at least one of the
tests being positive for 98.0% of patients with CNS histoplasmosis (1). Although a serum
assay to detect (1,3)--D-glucan (BDG), a fungal cell wall polysaccharide, has been
cleared by the U.S. Food and Drug Administration for serological diagnosis of invasive
fungal diseases since 2004, the assay is not approved for CSF testing. Elevated levels of
BDG have been detected in the CSF of patients with fungal meningitis caused by
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Candida sp. (2, 3), Aspergillus (2, 4), Exserohilum (5, 6), Cryptococcus (4, 7), and Coccid-
ioides (8). Data on the utility of BDG in the diagnosis of Histoplasma meningitis are
limited (4, 9). We evaluated CSF BDG detection using the Fungitell assay in the largest
series of patients with CNS histoplasmosis to date.
MATERIALS AND METHODS
Cases were classiﬁed using previously deﬁned criteria (1). Patients were categorized as CNS histo-
plasmosis cases if they had clinical symptoms of meningitis and/or brain imaging abnormalities and
supporting laboratory ﬁndings, as follows: conﬁrmed CNS histoplasmosis, isolation of Histoplasma
capsulatum from CSF; probable CNS histoplasmosis, detection of Histoplasma antigen by enzyme
immunoassay (EIA) or anti-Histoplasma antibodies in the CSF by immunodiffusion (ID) or complement
ﬁxation (CF); possible CNS histoplasmosis, pulmonary or disseminated histoplasmosis with CSF pleocy-
tosis but without laboratory conﬁrmation of CNS involvement (negative or absent culture ﬁndings,
microscopy ﬁndings, and detection of antigen or antibody by ID or CF in the CSF) and no alternative
etiology for the CSF pleocytosis. Controls included patients with pulmonary or disseminated histoplas-
mosis without CNS involvement (no clinical ﬁndings for meningitis, no pleocytosis or CNS imaging
abnormalities, and no diagnosis of or treatment for CNS histoplasmosis) or with negative testing for
histoplasmosis (either with or without CSF pleocytosis), including patients with meningitis due to fungal
pathogens other than Histoplasma, nonfungal meningitis, and noninfectious CNS disorders.
BDG levels were measured in the remaining stored CSF specimens using the Fungitell assay,
according to the methods used for serum specimens, as reported previously for CSF (4, 5). Data regarding
prior treatment were not available when CSF specimens were obtained. According to the manufacturer’s
guidelines for serum BDG assays, a positive CSF BDG result was deﬁned as 80 pg/ml. Chi-square
analysis, Student’s t test, and the step-down Bonferroni multiple-comparison procedure were used to
compare subgroups, using MedCalc software.
RESULTS
Forty-seven subjects with CNS histoplasmosis were enrolled in the study, including
9 (19.1%) conﬁrmed, 33 (70.2%) probable, and 5 (10.6%) possible cases. A total of 153
subjects without CNS histoplasmosis were included as controls, including 13 (8.5%)
with other causes of fungal meningitis, 31 (20.3%) with nonfungal meningitis, and 109
(71.2%) with noninfectious CNS disorders (e.g., encephalopathy or seizure disorder).
Ten of 11 controls with pulmonary or disseminated histoplasmosis had a noninfectious
CNS disorder, and 1 had Toxoplasma encephalitis. Cultures were positive for fungal
pathogens for 6 (5.1%) of 117 controls for whom cultures were performed; pathogens
included Cryptococcus (n  4), Aspergillus (n  1), and Candida dubliniensis (n  1). The
other 7 fungal meningitis control cases had the following: blastomycosis (n  3) (2
controls were diagnosed by CSF antigen, one with the organism being isolated from
bronchoalveolar lavage ﬂuid and the other with characteristic large, broad-based
budding yeast consistent with Blastomyces being identiﬁed with Grocott’s methena-
mine silver staining of leptomeninges from a postmortem specimen; the third control
had a positive urine antigen test result and a positive culture for Blastomyces from
bronchoalveolar lavage ﬂuid), cryptococcosis (n  1, diagnosed by antigen testing),
coccidioidomycosis (n  1, diagnosed by antibody testing), aspergillosis (n  1,
diagnosed by antigen testing), and candidiasis (n  1, diagnosed by blood culture).
Forty-nine percent of patients with CNS histoplasmosis and 43.8% of controls were
immunocompromised. BDG levels in the CSF among the different groups are shown in
Fig. 1.
CSF BDG levels were not signiﬁcantly different among the conﬁrmed, probable, and
possible cases of Histoplasma meningitis (P  0.93) (Table 1). The median BDG level for
cases was 85 pg/ml, compared to 31 pg/ml for all controls (P  0.05), 31 pg/ml for
nonfungal meningitis (P  0.05), and 31 pg/ml for noninfectious CNS disorders (P 
0.05). There were no signiﬁcant differences in median BDG levels between cases of
Histoplasma meningitis (85 pg/ml) and other fungal meningitis (82 pg/ml) (P  0.27).
Twenty-ﬁve of the 47 Histoplasma meningitis cases had CSF BDG levels of 80
pg/ml, resulting in a sensitivity of 53.2%. Of the 153 controls, 133 had CSF BDG levels
of80 pg/ml, resulting in an overall speciﬁcity of 86.9% for detection of BDG in CSF for
CNS histoplasmosis. Using the 140 controls without fungal meningitis, the speciﬁcity
was 90.7%; using the 11 controls with disseminated or pulmonary histoplasmosis
without CNS involvement, the speciﬁcity was 100%. Using the controls with other
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causes of fungal meningitis, however, the speciﬁcity was 46.2%. The median CSF BDG
level in 6 controls with culture-positive fungal CNS infections other than histoplasmosis
was 227 pg/ml, and 5 had levels of 80 pg/ml. Among the 7 controls with nonhisto-
plasmosis fungal CNS infections diagnosed by antigen testing, antibody testing, or
blood culture, the median BDG level was 61 pg/ml; 2 had CSF BDG levels of80 pg/ml.
Histoplasma meningitis cases with CSF BDG levels of 80 pg/ml were older than
those with BDG levels of 80 pg/ml (mean age, 47 years  7 versus 36 years  8;
P  0.03). There were no statistically signiﬁcant differences in sex (P  0.12),
immunocompromised status (P  0.89), positive CSF culture (P  0.56), positive
Histoplasma antigen testing (P  0.51), or the presence of high Histoplasma antigen
levels (19 ng/ml) (P  0.22) between cases with BDG levels of 80 and those with
levels of 80 pg/ml.
Among 37 patients with positive CSF Histoplasma antigen testing, the median BDG
level was 127.6 pg/ml; 21/37 patients (56.8%) had levels of 80 pg/ml, and 25/37
patients (67.6%) had levels of 31 pg/ml. Four of 25 cases with BDG levels of 80
pg/ml and 7 of 32 cases with BDG levels of 31 pg/ml had negative CSF Histoplasma
antigen testing. Two cases had positive CSF antigen test results that were below the
detectable limit of 0.4 ng/ml.
CSF BDG levels of 80 pg/ml were also detected in 13 patients with bacterial
meningitis or a brain abscess (n 3), viral encephalitis (n 1), Rocky Mountain spotted
fever (n  1), stroke (n  2), neurosarcoidosis (n  1), melanoma (n  1), hypoxic brain
FIG 1 CSF BDG levels in CNS Histoplasma meningitis, other fungal CNS infections, nonfungal CNS
infections, and noninfectious CNS disorders. The dashed line represents the value of 80 pg/ml. *, There
were 98 controls with noninfectious CNS disorders who had CSF BDG levels of 80 pg/ml.
TABLE 1 CSF BDG levels in different groups of Histoplasma meningitis cases and controls
Group No. of subjects
CSF BDG level (median
[IQR]) (pg/ml)
No. (%) with BDG level
of >80 pg/ml P
All cases 47 85 (31–194) 25 (53.2) Reference
Conﬁrmed 9 116 (62–197) 5 (55.6) 0.93a
Probable 33 85 (31–183) 18 (54.5)
Possible 5 72 (54–99) 2 (40.0)
All controls 153 31 (31 to 55) 20 (13.1) 0.05b
Other fungal meningitis 13 82 (61–234) 7 (53.8) 0.27b
Nonfungal meningitis 31 31 (31 to 55.5) 5 (16.1) 0.05b
Noninfectious CNS disorder 109 31 (31 to 44) 7 (6.4) 0.05b
aP for comparison of conﬁrmed, probable, and possible cases.
bP for comparison with cases.
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injury (n 1), acute psychosis (n 1), a seizure disorder (n 1), or an adverse reaction
to medication (n  1). The median BDG level was 134 pg/ml (interquartile range [IQR],
93 to 303 pg/ml).
Using the Youden method (10) for receiver operating characteristic (ROC) analysis,
the optimal cutoff value for CSF BDG levels was 61 pg/ml for CNS histoplasmosis versus
controls, including other fungal meningitis cases, with sensitivity of 63.8%, speciﬁcity of
79.7%, and area under the curve (AUC) of 0.706 (Fig. 2). When other fungal meningitis
cases were excluded, the optimal cutoff value for BDG was 58 pg/ml, yielding sensitivity
and speciﬁcity of 67.8% and 83.7%, respectively, for Histoplasma meningitis, compared
with nonfungal meningitis controls, and AUC of 0.767 (Fig. 3).
DISCUSSION
This is the ﬁrst large case series study to evaluate the detection of BDG in the CSF
of patients with Histoplasma meningitis. In this study, using the manufacturer’s recom-
mended cutoff value of 80 pg/ml, the sensitivity was 53.2% and the speciﬁcity was
86.9% when all controls were used. However, the speciﬁcity fell to 46% when only
controls with other types of fungal meningitis were used.
The optimal cutoff value is not well deﬁned for CSF BDG levels. For serum BDG
levels, the assay manufacturer recommends that60 pg/ml be interpreted as negative,
60 pg/ml to 79 pg/ml as intermediate, and 80 pg/ml as positive (11). Some authors
(6, 7) used80 pg/ml as a cutoff value for CSF BDG levels, whereas one author (8) used
31 pg/ml.
FIG 2 ROC curve of CSF BDG levels to distinguish histoplasmosis cases from all controls, including other
fungal meningitis controls. The AUC was 0.706.
FIG 3 ROC curve of CSF BDG levels to distinguish histoplasmosis cases from controls except for other
fungal meningitis controls. The AUC was 0.767.
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The sensitivity was lower than that for other types of fungal meningitis, such as
Exserohilum meningitis (84%) (5), cryptococcal meningitis (89%) (7), and coccidioidal
meningitis (96%) (8). The overall speciﬁcity in this study (87%) was comparable to that
reported for Exserohilum meningitis (95%) (5), cryptococcal meningitis (85%), and
coccidioidal meningitis (85%) (8), although the speciﬁcity of a diagnostic test depends
on the controls selected for comparison. BDG is not speciﬁc for Histoplasma, as
evidenced by the low speciﬁcity in comparison with other fungal meningitis controls.
However, CSF BDG levels may help distinguish a fungal CNS process from a nonfungal
process, based on the speciﬁcity of 90.7% when the cases were compared with controls
with a nonfungal neurological diagnosis. In addition, CSF BDG levels below the cutoff
value can help reassure clinicians that a patient with disseminated or pulmonary
histoplasmosis does not have CNS involvement.
We found that the sensitivity of detection of CSF BDG in Histoplasmameningitis was
lower than that of detection of BDG in other forms of fungal meningitis. Histoplasma
yeasts secrete -1,3-glucanases that remove exposed cell wall -glucans to minimize
host detection of Histoplasma yeasts (12), which may explain the lower sensitivity of
CSF BDG testing in Histoplasma meningitis, compared to the other causes of fungal
meningitis. Lower fungal burdens in the CSF in CNS histoplasmosis also might lead to
lower sensitivity of CSF BDG testing.
CSF BDG was also detected in 13 patients without a fungal CNS infection. The reason
for high CSF BDG levels in these nonfungal meningitis controls is unclear but could
represent false-positive results due to cross contamination at the time of processing
and testing, surgical gauze in the lumbar puncture kit (13), or the use of certain
antibiotics (14). False-positive serum BDG results can also occur with a history of
hemodialysis, blood transfusion, or intravenous immunoglobulin therapy.
Limitations of the study include its retrospective design and limited clinical and labo-
ratory data. For some subjects, CSF fungal culture, antigen detection, and antibody detec-
tion were not performed as part of clinical care, and thus results were not able to be
analyzed. Paired serum BDG testing results were not available. In summary, CSF BDG levels
of 80 pg/ml are not speciﬁc for a diagnosis of Histoplasma meningitis. Furthermore, CSF
BDG levels of 80 pg/ml cannot reliably rule out a diagnosis of CNS histoplasmosis.
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